| Recruitment status | Terminated |
| Unique ID issued by UMIN | UMIN000032200 |
| Receipt No. | R000036722 |
| Scientific Title | Multi-center study for efficacy of TAZ/PIPC on catheter-associated urinary tract infection (CAUTI) |
| Date of disclosure of the study information | 2018/04/11 |
| Last modified on | 2019/05/03 (Ver. 2) |
| Basic information | ||
| Public title | Multi-center study for efficacy of TAZ/PIPC on catheter-associated urinary tract infection (CAUTI) | |
| Acronym | Efficacy of TAZ/PIPC on catheter-associated urinary tract infection (CAUTI) | |
| Scientific Title | Multi-center study for efficacy of TAZ/PIPC on catheter-associated urinary tract infection (CAUTI) | |
| Scientific Title:Acronym | Efficacy of TAZ/PIPC on catheter-associated urinary tract infection (CAUTI) | |
| Region |
|
|
| Condition | ||
| Condition | Catheter-associated urinary tract infection | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To investigate the efficacy of Tazobactam/Piperacillin (TAZ/PIPC) on catheter-associated urinary tract infection (CAUTI) |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | TAZ/PIPC 13.5g/day treatment on CAUTI will be done for 1 week and 1st outcome evaluation will be don, then antibiotics will be switched to oral one by de-escalation for another a week. Then, 2nd outcome evaluation will be done. Then, after 1 week of no-administration of antibiotics, 3rd outcome evaluation will be undertaken.Basically outcome evaluation is done by symptom of infectious diseases. |
| Key secondary outcomes | |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | TAZ/PIPC group 13.5g/day for 1 week | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Those patients with CAUTI who are older than 20 years old. | |||
| Key exclusion criteria | Those patients with allergy for TAZ/PIPC.
Those patients with the previous UTI whiose causative bacteria showed TAZ/PIPC-resistance. |
|||
| Target sample size | 100 | |||
| Research contact person | |||||||
| Last name of lead principal investigator |
|
||||||
| Organization | Kobe University | ||||||
| Division name | Urology | ||||||
| Zip code | |||||||
| Address | 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, | ||||||
| TEL | 078-382-6155 | ||||||
| masato@med.kobe-u.ac.jp | |||||||
| Public contact | |||||||
| 1st name of contact person |
|
||||||
| Organization | Kobe University | ||||||
| Division name | Urology | ||||||
| Zip code | |||||||
| Address | 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, | ||||||
| TEL | 078-382-6155 | ||||||
| Homepage URL | |||||||
| katsumi@med.kobe-u.ac.jp | |||||||
| Sponsor | |
| Institute | Kobe University |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Kobe University |
| Organization | |
| Division | |
| Category of Funding Organization | Other |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | |
| Address | |
| Tel | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Terminated | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000036722 |